Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 7, 2000, Pages 861-867

  Lind, T ^a   Rydberg, L ^a   Kyleback A ^a   Jonsson, A ^a   Andersson, T ^b   Hasselgren, G ^c   Holmberg, J ^c   Rohss K ^c  

^a Department of Surgery ^*  (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; STOMACH PH;

ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; STEREOISOMERISM;

EID: 0033947414     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00813.x     Document Type: Article

References (16)

1. 1 Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57.
2. 2 Smith JL, Operkun AR, Larkai E, Graham DY. Sensitivity of oesophageal mucosa to pH in gastro-oesophageal reflux disease. Gastroenterology 1989; 96: 683-9.
3. 3 Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
4. 4 Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11(Suppl. B): 66B-73B.
5. 5 Chiba N, de Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
6. 6 Dent J, Brun J, Fendrick AM, et al. on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44(Suppl. 2): S1-S16.
7. 7 Andersson T, Röhss K, Hassan-Alin M, Bredberg E. Pharmacokinetics and dose-response relationship of esomeprazole (abstract). Gastroenterology 2000; 118: A1210.
8. 8 Hassan-Alin M, Röhss K, Andersson T, Nyman L. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects (abstract). Gastroenterology 2000; 118: A16.
9. 9 Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984; 309: 347-56.
10. 10 Joelsson B, Johnsson F. Heartburn - the acid test. Gut 1989; 30: 1523-5.
11. 11 Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6.
12. 12 Houben GM, Hooi J, Hameeteman W, Stockbrügger RW. Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. Aliment Pharmacol Ther 1995; 9: 649-54.
13. 13 Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013-23.
14. 14 Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol 1995; 20(Suppl. 1): S7-S9.
15. 15 Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49.
16. 16 Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45-52.